Related Experiment Video
Updated: Mar 30, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Fenofibrate-induced massive regression of mutiple inflammatory hepatocellular adenoma
Raoul Poupon1, Dominique Cazals-Hatem2, Lionel Arrivé3
1Service d'hépatologie, hôpital Saint-Antoine, AP-HP, Paris, France.
Abstract:
Inflammatory hepatocellular adenomas (IHCA), which accounts for 40% to 50% of all hepatocellular adenomas are characterized by the activation of the IL6/JAK/STAT pathway. We herein report the case of a 52-year-old woman presenting with severe multiple typical IHCA that regressed dramatically on treatment with fenofibrate, a PPAR agonist known to prevent IL6-induced inflammation experimentally and in humans. Further similar observations are needed to ascertain the potential benefit of this therapeutic approach for large or unresectable IHCA.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hepatic Drug Excretion: Influencing Factors

